After launching it's new Hydrobiome Serum — a formulation that addresses redness, congestion, and barrier disruption — in March, clinical skincare brand, Epicutis, released a study on its effectiveness.
In a double-blind, placebo-controlled clinical study (n=48, 8 weeks) conducted by Princeton Consumer Research, subjects using TCP — the proprietary active at the heart of Hydrobiome Serum — demonstrated a 77% improvement in overall skin appearance from baseline, versus 56% in the comparator group and no measurable improvement in the vehicle control. Critically, not a single participant reported visible irritation, dryness, or discomfort.
Related: Epicutis Launches Hydrobiome Serum With Biotech Ingredient TCP for Blemish-Prone Skin
"Hydrobiome Serum represents a more intelligent approach to supporting clear, healthy-looking skin. By leveraging our biotechnology platform — built on patented molecules that work at the membrane level — we're helping skin function as it was designed to: balanced, resilient, and self-regulating," said Maxwell Stock, who is the founder & CEO of Epicutis.
Hydrobiome Serum is available exclusively through licensed aesthetic professionals, dermatology practices, and accredited med-spa partners — consistent with Epicutis' commitment to physician-channel integrity and science-driven patient outcomes. It is not available through mass retail or direct-to-consumer e-commerce channels.
Authorized practitioners can inquire about stocking, clinical sampling, and patient education materials through the Epicutis professional portal at www.epicutis.com/professional.
